Pregnancy during TNFα antagonist therapy: Beware the rifampin-oral contraceptive interaction. Report of two cases

Joint Bone Spine

Volumn 77, Issue 3, 2010, Pages 268-270

  Wibaux, Cécile ^a   Andrei, Irina ^a   Paccou, Julien ^a   Philippe, Peggy ^a   Biver, Emmanuel ^a   Duquesnoy, Bernard ^a   Flipo, René Marc ^a  

^a LILLE UNIVERSITY HOSPITAL   (France)

Author keywords

Contraception; Drug drug interactions; Pregnancy; Rifampin; TNF antagonists

Indexed keywords

ADALIMUMAB; DAILY; DESOGESTREL PLUS ETHINYLESTRADIOL; ETHINYLESTRADIOL PLUS LEVONORGESTREL; INFLIXIMAB; ISONIAZID PLUS RIFAMPICIN; KETOPROFEN; ORAL CONTRACEPTIVE AGENT; PARACETAMOL; RIFAMPICIN; SALAZOSULFAPYRIDINE; TUMOR NECROSIS FACTOR ALPHA INHIBITOR; UNCLASSIFIED DRUG; ANTIRHEUMATIC AGENT; ISONIAZID; TUBERCULOSTATIC AGENT; TUMOR NECROSIS FACTOR ALPHA;

ADULT; ANKYLOSING SPONDYLITIS; ARTICLE; CASE REPORT; DRUG INHIBITION; DRUG TREATMENT FAILURE; ECHOGRAPHY; FEMALE; HUMAN; LUNG TUBERCULOSIS; PREGNANCY; PREGNANCY TEST; PRENATAL CARE; SACROILIITIS; SKIN INDURATION; THORAX RADIOGRAPHY; TREATMENT RESPONSE; TUBERCULIN TEST; DRUG ANTAGONISM; DRUG INTERACTION; IMMUNOCOMPROMISED PATIENT; IMMUNOLOGY;

ADULT; ANTIRHEUMATIC AGENTS; ANTITUBERCULAR AGENTS; CONTRACEPTIVES, ORAL; DRUG INTERACTIONS; FEMALE; HUMANS; IMMUNOCOMPROMISED HOST; ISONIAZID; PREGNANCY; RIFAMPIN; SPONDYLITIS, ANKYLOSING; TUBERCULOSIS, PULMONARY; TUMOR NECROSIS FACTOR-ALPHA;

EID: 77953125077     PISSN: 1297319X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jbspin.2010.02.001     Document Type: Article

References (14)

1. Agence française de sécurité sanitaire des produits de santé. Recommandations nationales : prévention et prise en charge des tuberculoses survenant sous anti-TNFα. 2005. http://www.afssaps.fr/content/download/12022/143647/version/2/file/reco.pdf.
2. Roux C.H., Brocq O., Breuil V., et al. Pregnancy in rheumatology patients exposed to anti-tumour necrosis factor (TNF)-α therapy. Rheumatology 46 (2007) 695-698
3. Berthelot J.M., De Bandt M., Goupille P., et al. Exposition to anti-TNF drugs during pregnancy. Outcome of 15 cases and review of the literature. Joint Bone Spine 76 (2009) 32-38
4. Strangfeld A., Listing J., Rau R., et al. Pregnancy outcome after exposure to biologics: results from the German Biologics Register RABBIT. Arthritis Rheum 56 Suppl. (2007) 311-312
5. American Thoracic Society. Targeted tuberculin testing and treatment of latent tuberculosis infection. MMWR Recomm Rep 2000;49:1-51.
6. British Thoracic Society Standards of Care Committee. BTS recommendations for assessing risk and managing mycobacterium tuberculosis infection and disease in patients due to start anti-TNF-α treatment. Thorax 2005;60:800-5.
7. Dickinson B.D., Altman R.D., Nielsen N.H., et al. Drug interactions between oral contraceptives and antibiotics. Obstet Gynecol 98 (2001) 853-860
8. Archer J.S., and Archer D.F. Oral contraceptive efficacity and antibiotic interaction: a myth debunked. J Am Acad Dermatol 46 (2002) 917-923
9. Carter J.D., Ladhani A., Ricca L., et al. A safety assessment of TNF antagonists during pregnancy: a review of the FDA database. Arthritis Rheum 56 Suppl. (2007) 286-287
10. Johnson D.L., Jones K.L., Chambers C., et al. Pregnancy outcomes in women exposed to etanercept: the OTIS autoimmune disease in pregnancy project. Arthritis Rheum 58 Suppl. (2008) 682
11. Johnson D.L., Jones K.L., Chambers C., et al. Pregnancy outcomes for women exposed to adalimumab: the OTIS autoimmune diseases in pregnancy project. Arthritis Rheum 58 Suppl. (2008) 682-683
12. Østensen M., Lockshin M., Doria A., et al. Update on safety during pregnancy of biological agents and some immunosuppressive anti-rheumatic drugs. Rheumatology 47 Suppl. 3 (2008) iii28-31
13. Centre de références sur les agents tératogènes. http://www.crat.org/articlesearchSaisie.php3.
14. Greenaway J.C., and Fantel A.G. Enhancement of rifampin teratogenicity in cultured rat embryos. Toxicol Appl Pharmacol 69 (1983) 81-88